The role of long-acting bronchodilators in the management of stable COPD.

Bronchodilators form the foundation of symptomatic treatment of COPD. Several long-acting bronchodilators are now available for use in COPD, but publications of large-scale studies of their efficacy have, for the most part, postdated the publication of major clinical guidelines. This article provides a critical review of large (> or =50 patients), double-blind, clinical trials of three long-acting bronchodilators in COPD (the once-daily anticholinergic tiotropium, and the twice-daily beta(2)-agonists formoterol and salmeterol) within the context of the objectives of treatment defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. Fourteen published studies were identified, of which 12 studies were published since the release of the GOLD guidelines. All three long-acting bronchodilators were found to effectively improve lung function; however, they differed in their effects on outcomes other than bronchodilation, with salmeterol demonstrating inconsistent efficacy compared with placebo in preventing exacerbations and improving health status, and only tiotropium demonstrating consistent superiority to the short-acting bronchodilator ipratropium. Based on this review, a treatment algorithm for the introduction of long-acting bronchodilators to patients with COPD is proposed, which includes the use of long-acting bronchodilators early in the treatment algorithm.

[1]  V. Brusasco,et al.  Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.

[2]  N. Thomson,et al.  Managing chronic obstructive pulmonary disease. , 2003, The Practitioner.

[3]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[4]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[5]  J. Yates,et al.  Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[6]  R. Pauwels,et al.  Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD. , 2002, Respiratory medicine.

[7]  E. Bateman,et al.  A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. , 2002, Chest.

[8]  R. Goldstein,et al.  The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease. , 2002, Canadian respiratory journal.

[9]  M. Decramer,et al.  Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial , 2002, European Respiratory Journal.

[10]  G. Della Cioppa,et al.  Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. , 2002, Chest.

[11]  P. Jones.  Interpreting thresholds for a clinically significant change in health status in asthma and COPD , 2002, European Respiratory Journal.

[12]  R. Zuwallack,et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[13]  J. V. van Noord,et al.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium , 2002, European Respiratory Journal.

[14]  B. Smith,et al.  Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. , 2001 .

[15]  G. D. Cioppa,et al.  Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. , 2002, Canadian respiratory journal.

[16]  D. Benhamou,et al.  Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). , 2001, Respiratory medicine.

[17]  R. Dahl,et al.  Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[18]  S. Rennard,et al.  Alternative Mechanisms for Long-Acting β2-Adrenergic Agonists in COPD , 2001 .

[19]  R. Zuwallack,et al.  Salmeterol plus theophylline combination therapy in the treatment of COPD. , 2001, Chest.

[20]  M. De Salvo,et al.  In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study. , 2001, Chest.

[21]  R. Zuwallack,et al.  Use of a Long-acting Inhaled β2-Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease , 2001 .

[22]  B. Disse.  Antimuscarinic treatment for lung diseases from research to clinical practice. , 2001, Life sciences.

[23]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[24]  M. Cazzola,et al.  Additive effects of salmeterol and fluticasone or theophylline in COPD. , 2000, Chest.

[25]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[26]  W. Hop,et al.  Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. , 2000, The European respiratory journal.

[27]  R. Rodríguez-Roisín,et al.  Toward a consensus definition for COPD exacerbations. , 2000, Chest.

[28]  M. R. Mölken,et al.  An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. , 1999, Thorax.

[29]  M. Johnson,et al.  Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro. , 1999, The European respiratory journal.

[30]  A. Fryer,et al.  Interaction of viral infections with muscarinic receptors , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[31]  S. Yancey,et al.  Efficacy of salmeterol xinafoate in the treatment of COPD. , 1999, Chest.

[32]  M. Cazzola,et al.  Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. , 1998, Chest.

[33]  M. Johnson,et al.  Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. , 1998, The European respiratory journal.

[34]  A. Morice,et al.  An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) , 1997, The European respiratory journal.

[35]  P. Jones,et al.  Quality of life changes in COPD patients treated with salmeterol. , 1997, American journal of respiratory and critical care medicine.

[36]  S. Rennard,et al.  Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. , 1996, Chest.

[37]  P. Jones,et al.  Issues concerning health-related quality of life in COPD. , 1995, Chest.

[38]  P. Barnes.  Bronchodilators: Basic Pharmacology , 1995 .

[39]  A. Buist,et al.  In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: An 85-day multicenter trial , 1994 .

[40]  P. Barnes.  Muscarinic receptor subtypes in airways. , 1993, Life sciences.

[41]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.

[42]  N. Gross,et al.  Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. , 1989, Chest.

[43]  J. Paterson,et al.  Beta-adrenoceptor function in asthmatic bronchial smooth muscle. , 1988, General pharmacology.

[44]  G. Guyatt,et al.  A measure of quality of life for clinical trials in chronic lung disease. , 1987, Thorax.

[45]  N. Anthonisen,et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.

[46]  C. Wells,et al.  The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. , 1984, Chest.